Skip to main content
Login
Contact
Subscribe
Search form
Search
The Sweetwater Reporter
Home
Forms
News
Sports
Classifieds
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Photos
Videos
Games
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Bristol-Myers Squibb
(NY:
BMY
)
56.90
USD
UNCHANGED
Streaming Delayed Price
/ Updated:
7:56 PM EDT, Apr 7, 2020
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
56.90
Bid (Size)
55.86 (2)
Ask (Size)
59.28 (2)
Prev. Close
56.90
Today's Range
56.90 - 56.90
52wk Range
42.48 - 68.34
Shares Outstanding
1,634,538,458
Dividend Yield
2.81%
Performance
YTD
-10.17%
-10.17%
1 Month
+1.34%
+1.34%
3 Month
-11.00%
-11.00%
6 Month
+12.99%
+12.99%
1 Year
+21.61%
+21.61%
Top News
More News
Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.
April 07, 2020
category
Sustainable Development Goals
,
pandemic
,
Responsible Business & Employee Engagement
, and 9 more.
from
3BL Media: Corporate Social Responsibility, Energy and Health News
Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.
April 07, 2020
Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the...
Read More
from
Business Wire News Releases
More News
Read More
U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
April 03, 2020
from
Business Wire News Releases
Over 35 Companies In Race To Develop Vaccine For COVID-19 Health Crises
March 31, 2020
category
Featured News
from
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Over 35 Companies in Race to Develop Vaccine for COVID-19 Health Crises
March 31, 2020
from
PR Newswire
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.
March 31, 2020
category
BSGM News
from
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.
March 31, 2020
from
GlobeNewswire News Releases
Merck's Keytruda Receives Priority Review for a Key Indication
April 07, 2020
category
Market News
,
MRK
,
BMY
from
Motley Fool
Former Celgene Drug Earns a Key Approval for Bristol Myers Squibb
April 06, 2020
category
BMY
,
Market News
from
Motley Fool
Thinking about trading options or stock in Bristol-Myers Squibb, Chevron Corp, Docusign, Intel Corp, or Tesla?
April 03, 2020
from
PR Newswire
Should You Buy Illumina Stock During the Coronavirus Bear Market?
April 05, 2020
category
Market News
,
PACB
,
BMY
, and 3 more.
from
Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
